Allergic Contact Dermatitis in Atopic Individuals: Results of a 30-year Retrospective Study

Atopic Dermatitis

Pediatric Contact Dermatitis Registry Data on Contact Allergy in Children With Atopic Dermatitis

JAMA Dermatol.

Jacob SE, McGowan M, Silverberg NB, Pelletier JL, Fonacier L, Mousdicas N, Powell D, Scheman A, Goldenberg A

doi: 10.1001/jamadermatol.

Atopic Dermatitis

Dupilumab provides favourable long-term safety and efficacy in children aged ≥ 6 to < 12 years with uncontrolled, severe atopic dermatitis: results from an open-label phase IIa study and subsequent phase III open-label extension study

Br J Dermatol

Cork MJ, Thaçi D, Eichenfield LF, Arkwright PD, Sun X, Chen Z, Akinlade B, Boklage S, Guillemin I, Kosloski MP, Kamal MA, O'Malley JT, Patel N, Graham NMH, Bansal A

doi: 10.1111/bjd.19460

Atopic Dermatitis

Association between atopic dermatitis and contact sensitization: A systematic review and meta-analysis

J Am Acad Dermatol.

Hamann CR, Hamann D, Egeberg A, Johansen JD, Silverberg J, Thyssen JP

doi: 10.1016/j.jaad.2017.02.001.

Atopic Dermatitis

Dupilumab provides favourable long-term safety and efficacy in children aged ≥ 6 to < 12 years with uncontrolled, severe atopic dermatitis: results from an open-label phase IIa study and subsequent phase III open-label extension study

Br J Dermatol.

Cork MJ, Thaçi D, Eichenfield LF, Arkwright PD, Sun X, Chen Z, Akinlade B, Boklage S, Guillemin I, Kosloski MP, Kamal MA, O'Malley JT, Patel N, Graham NMH, Bansal A

doi: 10.1111/bjd.19460.

Atopic Dermatitis

Nemolizumab plus topical agents in patients with atopic dermatitis and moderate-to-severe pruritus provide improvement in pruritus and signs of atopic dermatitis for up to 68 weeks: results from two phase III, long-term studies

Br J Dermatol

Kabashima K, Matsumura T, Komazaki H, Kawashima M, Nemolizumab JP01, JP02 Study Group.

doi: 10.1111/bjd.20873

Atopic Dermatitis

Atopic dermatitis and risk of atrial fibrillation or flutter: a 35-year follow-up study

J Am Acad Dermatol.

Schmidt SAJ, Olsen M, Schmidt M, Vestergaard C, Langan SM, Deleuran MS, Riis JL

doi: 10.1016/j.jaad.2019.08.039.

Atopic Dermatitis

Use of Dupilumab for 543 Adult Patients with Moderate-To-Severe Atopic Dermatitis: A Multicenter, Retrospective Study

J Investig Allergol Clin Immunol.

Nettis E, Ferrucci SM, Ortoncelli M, Pellacani G, Foti C, Di Leo E, Patruno C, Rongioletti F, Argenziano G, Macchia L, Tavecchio S, Napolitano M, Ribero S, Bonzano L, Romita P, Di Bona D, Nisticò SP, Piras V, Calabrese G, Detoraki C, Carbonara M, Fabbrocini G

doi: 10.18176/jiaci.0641.

Atopic Dermatitis

Factors associated with improvement of quality of life among parents of children with atopic dermatitis: one-year prospective cohort study

J Eur Acad Dermatol Venereol.

Maksimovic N, Zaric M, Reljic V, Nikolic M, Gazibara T

doi: 10.1111/jdv.15939.

Atopic Dermatitis

Novel systemic drugs in treatment of atopic dermatitis: results from phase II and phase III studies published in 2017/2018

Curr Opin Allergy Clin Immunol.

Werfel T

doi: 10.1097/

Related content

Pediatric Contact Dermatitis Registry Data on Contact Allergy in Children With Atopic Dermatitis

Dupilumab provides favourable long-term safety and efficacy in children aged ≥ 6 to < 12 years with uncontrolled, severe atopic dermatitis: results from an open-label phase IIa study and subsequent phase III open-label extension study

Association between atopic dermatitis and contact sensitization: A systematic review and meta-analysis

Dupilumab provides favourable long-term safety and efficacy in children aged ≥ 6 to < 12 years with uncontrolled, severe atopic dermatitis: results from an open-label phase IIa study and subsequent phase III open-label extension study

Nemolizumab plus topical agents in patients with atopic dermatitis and moderate-to-severe pruritus provide improvement in pruritus and signs of atopic dermatitis for up to 68 weeks: results from two phase III, long-term studies

Atopic dermatitis and risk of atrial fibrillation or flutter: a 35-year follow-up study

Use of Dupilumab for 543 Adult Patients with Moderate-To-Severe Atopic Dermatitis: A Multicenter, Retrospective Study

Factors associated with improvement of quality of life among parents of children with atopic dermatitis: one-year prospective cohort study

Novel systemic drugs in treatment of atopic dermatitis: results from phase II and phase III studies published in 2017/2018